- Home
- INCY vs BLDR Comparison
INCY vs BLDR Comparison
Compare INCY & BLDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | BLDR |
|---|---|---|
| Founded | 1991 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 13.9B |
| IPO Year | 1993 | 2005 |
Fundamental Metrics
Financial Performance| Metric | INCY | BLDR |
|---|---|---|
| Price | $102.54 | $110.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 18 |
| Target Price | $90.71 | ★ $143.89 |
| AVG Volume (30 Days) | 2.0M | ★ 2.5M |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3878.02 | N/A |
| EPS | ★ 5.90 | 5.26 |
| Revenue | $4,813,105,000.00 | ★ $15,653,056,000.00 |
| Revenue This Year | $19.59 | N/A |
| Revenue Next Year | $10.88 | N/A |
| P/E Ratio | ★ $17.37 | $20.93 |
| Revenue Growth | ★ 18.09 | N/A |
| 52 Week Low | $53.56 | $94.35 |
| 52 Week High | $109.28 | $179.93 |
Technical Indicators
Market Signals| Indicator | INCY | BLDR |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 49.68 |
| Support Level | $100.55 | $109.75 |
| Resistance Level | $107.61 | $116.31 |
| Average True Range (ATR) | 2.94 | 4.31 |
| MACD | -0.98 | 1.71 |
| Stochastic Oscillator | 45.19 | 71.54 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About BLDR Builders FirstSource Inc.
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.